Replies to post #111324 on Vivos Inc (RDGL)

[gonetopot]

Bayer even bought a company to help and they still can't do it without damaging the surrounding tissue. The are shooting for an acceptable amount of damage! What acceptable damage?
Maybe they should buy RDGL. Here is your proof:

explains Dr. Alan Cuthbertson, Head of Thorium Research at Bayer in Oslo, Norway. He and his team were part of Algeta ASA, a company that was acquired by Bayer in 2013. These specialists in the use of alpha particle-emittting radionuclides in radiotherapy are working on a means of transporting thorium directly to the tumor where the radioisotope first accumulates and then decays, releasing the alpha particles. “The radiation then destroys cancer cells without da­maging the surrounding healthy tissue too severely,” explains the Bayer chemist.

https://www.research.bayer.com/en/fighting-cancer-with-radio-immunotherapy.aspx

[eros]

Radiation therapy is administered in two ways.
One way is via radiation beam from far away,this requires repeated treatments 4 to six weeks
The other way is brachytherapy,meaning that the radiation is being administered close to the tumor by implanting radioactive particles into the tumor bed and the tumor gets bombarded continuously.
From what I understand the radiogel is a form of brachytherapy but instead of radioactive sheeds they have found a way to inject the Ytrium 90 in a liquid form directly into the tumor with satisfactory distribution and also with shorter wave of radiation which avoids distraction of neighboring healthy tissues.
Additionally the duration of radioactivity is much less about 12 days because the half life of radiogel Y 90 is very short.
The issue here is that this could be applied in humans in many deferent cancers in the body.